BioLineRx Ltd.
NASDAQ Capital MarketTotal Valuation
BioLineRx Ltd. carries a market capitalization of 10.55M, placing it among publicly traded companies globally. Its enterprise value stands at 8.18B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 10.55M |
| Enterprise Value | 8.18B |
Share Statistics
BioLineRx Ltd. currently has 2.62B shares outstanding.
| Shares Outstanding | 2.62B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 9.88, and the price-to-book ratio stands at 593.86.
| PE Ratio | N/A |
| PS Ratio | 9.88 |
| PB Ratio | 593.86 |
| P/TBV Ratio | -3,196.81 |
| P/FCF Ratio | -1.28 |
| P/OCF Ratio | -1.27 |
Enterprise Valuation
| EV / Sales | 5,872.96 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
BioLineRx Ltd. maintains a current ratio of 1.20, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 47.78, indicating elevated leverage, while an interest coverage ratio of -11.67 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.20 |
| Quick Ratio | 1.01 |
| Debt / Equity | 47.78 |
| Debt / EBITDA | -0.67 |
| Interest Coverage | -11.67 |
Financial Efficiency
| Return on Equity (ROE) | -41.30 |
| Return on Assets (ROA) | -18.21 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.11 |
Stock Price Statistics
BioLineRx Ltd.'s stock has declined approximately -43.31551% over the past 52 weeks. The 50-day moving average sits at 2.52, while the 200-day moving average is 2.78.
| Beta (5Y) | N/A |
| 52-Week Price Change | -43.31551% |
| 50-Day Moving Average | 2.52 |
| 200-Day Moving Average | 2.78 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, BioLineRx Ltd. generated 1.39M in revenue and converted that into -6.99M in net income, yielding earnings per share of -2.30. EBITDA reached -11.82M, while operating income came in at -12.17M.
| Revenue | 1.39M |
| Gross Profit | 1.11M |
| Operating Income | -12.17M |
| Pretax Income | -10.14M |
| Net Income | -6.99M |
| EBITDA | -11.82M |
| EBIT | -12.17M |
| Earnings Per Share (EPS) | -2.30 |
Balance Sheet
BioLineRx Ltd. holds 13.08M in cash and equivalents against 7.94M in total debt, resulting in a net debt position of 2.07M. Total book value stands at 13.77M, with working capital of 2.67M providing operational flexibility.
| Cash & Cash Equivalents | 13.08M |
| Total Debt | 7.94M |
| Net Debt | 2.07M |
| Equity (Book Value) | 13.77M |
| Book Value Per Share | 0.01 |
| Working Capital | 2.67M |
Cash Flow
BioLineRx Ltd. produced -10.80M in operating cash flow over the past twelve months. After subtracting -31,000.00 in capital expenditures, free cash flow totaled -10.83M - equivalent to -2.46 per share.
| Operating Cash Flow | -10.80M |
| Capital Expenditures | -31,000.00 |
| Free Cash Flow | -10.83M |
| FCF Per Share | -2.46 |
Margins
BioLineRx Ltd. operates with a gross margin of 80.03, reflecting its pricing power and cost economics. The operating margin of -874.28 and net profit margin of -502.08 provide insight into operational efficiency.
| Gross Margin | 80.03 |
| Operating Margin | -874.28 |
| Pretax Margin | -728.45 |
| Profit Margin | -502.08 |
| EBITDA Margin | -849.28 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.05 |
| FCF Yield | -78.35 |
Stock Splits
BioLineRx Ltd.'s most recent stock split took place on January 30, 2025 with a 40:1 split ratio.
| Last Split Date | 1/30/2025 |
| Split Ratio | 40:1 |
Scores
BioLineRx Ltd. posts an Altman Z-Score of 255.81, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 255.81 |